they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term